ストックスクリーナーアプリを入手
33.72
4.48%
1.445
アフターアワーズ：
34.18
0.46
+1.36%
前日終値:
$32.27
開ける：
$32.25
24時間の取引高:
2.41M
Relative Volume:
1.29
時価総額：
$2.43B
収益：
-
当期純損益:
$-368.95M
株価収益率:
-6.0808
EPS:
-5.5453
ネットキャッシュフロー:
$-293.81M
1週間 パフォーマンス:
+6.61%
1か月 パフォーマンス:
-4.88%
6か月 パフォーマンス:
-20.42%
1年 パフォーマンス:
+49.40%
1日の値動き範囲:
$32.02
$35.09
1週間の範囲:
$30.72
$35.09
52週間の値動き範囲:
$21.15
$56.05
Vera Therapeutics Inc Stock (VERA) Company Profile
名前
Vera Therapeutics Inc
セクター
電話
650-770-0077
住所
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
Compare VERA vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VERA
Vera Therapeutics Inc
|
33.72 | 2.25B | 0 | -368.95M | -293.81M | -5.5453 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vera Therapeutics Inc Stock (VERA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-11 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2025-10-16 | 開始されました | BofA Securities | Buy |
| 2025-08-04 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2025-05-05 | 再開されました | H.C. Wainwright | Buy |
| 2025-02-04 | 開始されました | Wolfe Research | Outperform |
| 2025-01-28 | 開始されました | Goldman | Buy |
| 2024-11-21 | 開始されました | Wells Fargo | Overweight |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-01-25 | 開始されました | Oppenheimer | Outperform |
| 2024-01-08 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-12-18 | 開始されました | Raymond James | Outperform |
| 2023-11-10 | アップグレード | Jefferies | Hold → Buy |
| 2023-08-16 | 開始されました | Guggenheim | Buy |
| 2023-01-04 | ダウングレード | Jefferies | Buy → Hold |
| 2023-01-04 | ダウングレード | Wedbush | Outperform → Neutral |
| 2022-07-12 | 開始されました | JP Morgan | Overweight |
| 2022-05-02 | 開始されました | H.C. Wainwright | Buy |
| 2022-04-19 | 開始されました | Wedbush | Outperform |
すべてを表示
Vera Therapeutics Inc (VERA) 最新ニュース
VERA Stock Surges After Drug To Treat Rare Kidney Disease Gets FDA Approval – Retail Sees The Move As Catalyst For Vera Therapeutics - Stocktwits
Nancy Lee Boman Net Worth (2026) - GuruFocus
Vera Therapeutics (NASDAQ:VERA): What Could Drive the Next Move? - Kalkine Media
What Vera Therapeutics (VERA)'s Widening Losses and Cash Burn Mean For Shareholders - Sahm
Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
H.C. Wainwright Maintains Vera Therapeutics(VERA.US) With Buy Rating, Cuts Target Price to $90 - Moomoo
Bank of America Corp DE Has $23.72 Million Stake in Vera Therapeutics, Inc. $VERA - MarketBeat
Vera Therapeutics upgraded to Buy after FDA nod for TRUTAKNA and positive kidney function data. - Pluang
Vera Therapeutics: FDA's eGFR Analysis Supports A Speculative Buy (NASDAQ:VERA) - Seeking Alpha
Wedbush Reiterates Neutral Rating for Vera Therapeutics (NASDAQ:VERA) - MarketBeat
J.P. Morgan Maintains Vera Therapeutics(VERA.US) With Buy Rating, Cuts Target Price to $76 - Moomoo
Vera Therapeutics Stock (VERA) Opinions on Positive eGFR Data Release - Quiver Quantitative
Vera Therapeutics Shares Up 9.7% as $425,000 Drug Launch Puts Focus on Cash Reserves - TechStock²
Vera Therapeutics Climbs as Investors React to TRUTAKNA Launch Progress and Near-Term IgAN Milestones - Quiver Quantitative
Kynam Capital (VERA) now holds 4.01% beneficial stake in Vera Therapeutics - Stock Titan
Vera Therapeutics (NASDAQ:VERA) Shares Gap UpHere's Why - MarketBeat
HC Wainwright Has Positive Estimate for VERA Q3 Earnings - MarketBeat
Vera stock rises on FDA review for kidney drug (VERA:NASDAQ) - Seeking Alpha
Is Vera Therapeutics (VERA) Undervalued On FDA Approval For TRUTAKNA? - Sahm
(VERA) Volatility Zones as Tactical Triggers - Stock Traders Daily
Vera Therapeutics president and CEO Marshall Fordyce sells $701,769 in stock - Investing.com
Vera Therapeutics president and CEO Marshall Fordyce sells $1.96m in stock - Investing.com
Vera Therapeutics CEO Marshall Fordyce sells $679,747 in stock - Investing.com
Vera Therapeutics (VERA) CEO trades 18,500 shares via 10b5-1 option exercise - Stock Titan
Vera Therapeutics (VERA) CEO option exercise and 18,500-share sale under 10b5-1 plan - Stock Titan
Goldman Sachs lowers Vera Therapeutics stock price target to $80 By Investing.com - Investing.com Nigeria
H.C. Wainwright cuts Vera Therapeutics stock price target on competition By Investing.com - Investing.com Nigeria
Vera Therapeutics (NASDAQ:VERA) Given New $90.00 Price Target at HC Wainwright - MarketBeat
H.C. Wainwright cuts Vera Therapeutics stock price target on competition - Investing.com India
E. Ohman J or Asset Management AB Acquires 42,787 Shares of Vera Therapeutics, Inc. $VERA - MarketBeat
Vera Therapeutics, Inc. Stock 12‑Month Price Target Cut to $81.21, Implies 157% Upside - TradingView
Wedbush Lowers Vera Therapeutics (NASDAQ:VERA) Price Target to $34.00 - MarketBeat
Vera Therapeutics (VERA) Stock Analysis: A Biotech With Potential 157.85% Upside - DirectorsTalk Interviews
Vera Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results - The Manila Times
VERA SWOT Analysis: Accelerated Approval of TRUTAKNA Marks a Key Milestone - GuruFocus
Vera Therapeutics Q2 Results: Net loss widens to $109.5 million - scanx.trade
Vera Therapeutics Q2 Results: EPS beats estimates despite wider losses - scanx.trade
Vera Therapeutics Q2 loss widens less than expected - TradingView
Vera Therapeutics (NASDAQ:VERA) Announces Quarterly Earnings Results - MarketBeat
Vera Therapeutics reports Q2 net loss of $109.5M as TRUTAKNA receives FDA accelerated approval - TradingView
Vera Therapeutics (VERA) ramps spending ahead of TRUTAKNA launch and posts $230.5M loss - Stock Titan
Vera's TRUTAKNA Gets FDA Accelerated Approval for IgA Nephropathy - Stock Titan
Dimensional Fund Advisors LP Decreases Stock Position in Vera Therapeutics, Inc. $VERA - MarketBeat
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
State Street Corporation (VERA) discloses 4.1M-share stake in Vera Therapeutics - Stock Titan
The Manufacturers Life Insurance Company Cuts Stock Position in Vera Therapeutics, Inc. $VERA - MarketBeat
Equity awards for Vera Therapeutics (VERA) Chief Regulatory Officer - Stock Titan
Vera Therapeutics under pressure in first earnings since approval By Investing.com - Investing.com Canada
Vera Therapeutics names Nancy Lee Boman as chief regulatory officer in initial beneficial ownership filing - Bitget
Vera Therapeutics, Inc. (VERA) Stock Analysis: A Biotech With 153% Potential Upside - DirectorsTalk Interviews
Vera Therapeutics (NASDAQ:VERA) Stock Price Down 5.8%Here's Why - MarketBeat
Vera Therapeutics Inc (VERA) 財務データ
収益
当期純利益
現金流量
EPS
Vera Therapeutics Inc (VERA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Fordyce Marshall | PRESIDENT AND CEO |
Jun 23 '26 |
Sale |
37.93 |
18,500 |
701,769 |
198,244 |
0.00%
3.22%
大文字化:
|
ボリューム (24 時間):